v3.26.1
SEGMENT REPORTING
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
We operate in a single reportable segment. The Chief Executive Officer is our Chief Operating Decision Maker, who primarily uses aggregated net loss as reported on the condensed statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. There have been no changes in the determination of segmentation or the measurements used to determine reported segment loss discussed in our 2025 Form 10-K. See Note 17. Segment Reporting of our 2025 Form 10-K for more discussion on our segment reporting.
Detailed information regarding our single operating segment’s significant revenues, expenses and operating loss is as follows:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2026202520262025
Revenues
Product sales, net$118,129 $90,077 $211,502 $157,891 
Other revenues(1)
2,748 7,585 3,848 13,885 
Total revenues120,877 97,662 215,350 171,776 
Less
Cost of product sales(2)
3,689 3,245 6,564 5,585 
Other cost of revenue(3)
2,070 9,158 4,006 19,121 
Research and development(4)
23,195 13,251 40,781 24,586 
Selling(4)
66,949 57,952 134,344 114,752 
General and administrative(4)
22,083 16,764 45,399 34,701 
Stock-based compensation15,316 11,687 29,474 23,775 
Loss from operations(12,425)(14,395)(45,218)(50,744)
Other reconciliation items(5)
(4,296)(4,684)(9,108)(9,479)
Net loss$(16,721)$(19,079)$(54,326)$(60,223)
(1)Other revenues includes revenues from our collaboration partnerships, including licensing revenue, product supply revenue and non-cash royalty revenue related to the sale of future royalties.
(2)Cost of product sales includes the cost of commercial goods sold to our Customers, such as the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process and indirect overhead costs.
(3)Other cost of revenue includes the cost of materials sold to our collaboration partners under product supply agreements, certain costs related to capacity expansion at current and future CMOs and payments due to AstraZeneca. As of the end of the 2025 second quarter, the maximum $75.0 million royalty obligation under the AstraZeneca Termination Agreement had been fully recognized.
(4)Research and development, selling and general and administrative expenses herein do not include stock-based compensation expenses.
(5)Other reconciliation items includes interest expense, non-cash interest expense related to the sale of future royalties, provision for income taxes and other income, net.